 Eighty to 90 of SCCHN squamous cell carcinoma of head and neck patients in Taiwan were betel quid chewers. Thirty to 40 of them experienced mucositis World Health Organization WHO grade 3 from cisplatinflurouracil FU in neoadjuvant chemotherapy setting. This was higher than the 8-11 reported in the Western populations and was related to oral submucous fibrosis from betel quid chewing.Severer toxicities, esp. mucositis, could be anticipated in patients of betel quid chewing treated by concurrent chemoradiotherapy CCRT with cisplatinFU.PG2 Injection is proved to be safe for clinical use and is effective in stimulating the recovery of hematopoiesis and immunity from chemotherapy-induced myelosuppression. It also improved the Quality of Life, especially in fatigue, among advanced cancer patients. This study will be investigated the effect of PG2 Injection in relieving the adverse events of concurrent chemoradiotherapy, such as fatigue, myelosuppression, mucositis, body weight loss, and even the compliance of radiotherapy and chemotherapy in treatment of patients with advanced pharyngeal or laryngeal SCCHN. 